Vasospastic Angina Refractory to Calcium-Channel Blockade: The Second-Line Choice
A maximized calcium-channel blocker has only partly controlled her coronary spasm, and the best-suited second-line drug for her situation isn't available in the country she lives in. The disagreement is about what to add instead.
S.P., a 48-year-old woman, has cut hair in the same salon for over twenty years, and the walk-in freezer where the supply stock is kept has become, without her ever choosing it that way, the most cardiologically significant square footage in her workday. Nearly every episode traces back to the same handful of seconds: she steps in for a box of color developer, and within a minute or two her chest tightens in a way that has nothing to do with exertion. She also wakes some nights with the same pain, unrelated to anything she was doing, which is what first sent her for the cardiac workup eight months ago — a workup that found nothing wrong with her coronary arteries on angiography, and everything explained instead by provocative testing that reproduced the spasm and the transient ST-elevation directly.
Diltiazem, titrated up over several months to a dose most cardiologists would call a genuine trial rather than a token attempt, has helped without solving the problem. She still has two or three episodes most weeks, still reaches for sublingual nitroglycerin several times over that same span, and the freezer at work remains, functionally, off-limits without planning around it. She smokes about half a pack a day, a habit she's trying to quit and one that is mechanistically relevant here in a way it wouldn't necessarily be for ordinary atherosclerotic angina — nicotine itself is a recognized trigger for coronary vasospasm, independent of any plaque it may eventually cause. She also carries a history of migraine with aura, a condition that shares enough vascular-reactivity biology with vasospastic angina that the overlap isn't considered coincidental. The question in front of her now isn't whether diltiazem was the right first step — it clearly was — but what to do when a high-dose calcium-channel blocker alone isn't holding the line: finish the climb to the labeled ceiling of 480 milligrams, or accept 360 as her working dose and add a second agent on top of it.
Reviewing a maximized calcium-channel blocker
I'd add a long-acting nitrate — isosorbide mononitrate — on top of the diltiazem. It's the most established second-line addition for vasospastic angina refractory to calcium-channel blocker monotherapy. The real caveat is nitrate tolerance with continuous dosing; she'll need a scheduled nitrate-free interval each day to preserve the benefit, not a round-the-clock dose. Her migraine history is a second caveat worth warning her about up front — nitrates provoke headache in a large minority of patients generally, and a migraineur is the patient most likely to find that intolerable and stop the drug without telling anyone.
In principle, nicorandil would be an excellent fit here — a potassium-channel opener with a distinct arterial and coronary vasodilatory mechanism that doesn't develop tolerance the way nitrates do, with real trial evidence in vasospastic and microvascular angina. I want to raise it and rule it out in the same breath: it isn't FDA-approved and isn't available in the United States. That's a genuine access barrier, not a clinical judgment call, and it takes the mechanistically best-suited option off the table for her regardless of how well it might otherwise fit.
If nitrate tolerance ends up limiting benefit, ranolazine is the practical next option actually available here — a distinct mechanism, late sodium current inhibition. I'd hold that one honestly, though: the two dedicated randomized trials in microvascular angina both missed their primary endpoints, and in vasospastic angina specifically there is essentially no trial base at all. It's a reasonable thing to try when the alternatives are exhausted, not an evidence-backed second line. One thing worth stating for the record even though nobody has proposed it: no beta-blocker. Unopposed alpha-mediated vasoconstriction can worsen spasm, and the reflex to treat anything called angina with a beta-blocker is exactly the reflex to name and block in a case like hers. I'd also reframe smoking cessation directly: it isn't an adjunct to whichever drug we add, it's a first-tier intervention on its own, given nicotine's documented role as a direct trigger for coronary vasospasm. Reducing her episode frequency doesn't have to wait on the drug conversation at all.
Agreed: add isosorbide mononitrate with a scheduled nitrate-free interval, continue diltiazem unchanged, start a structured smoking-cessation referral today rather than deferring it, and pre-treat with sublingual nitroglycerin before entering the walk-in freezer when it can't be avoided.
Not agreed, and the reason the plan carries a defined next step rather than an open-ended one:
Continue the current regimen and reassess in two months.
Move to ranolazine as the next addition, with nicorandil remaining off the table entirely due to access rather than clinical preference.